Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

SynBiotic SE, DE000A3E5A59

SynBiotic SE, DE000A3E5A59

12.10.2021 - 10:03:17

SynBiotic SE plans Canadian cross-listing

SynBiotic SE plans Canadian cross-listingMunich, October 12, 2021. The cannabis company SynBiotic SE (ISIN: DE000A2LQ777 / WKN: A2LQ77), already listed on the Frankfurt and D?sseldorf stock exchanges, is now to be listed on the Canadian NEO Exchange in Toronto - a new FinTech stock exchange that has been revolutionizing the market since 2014, offering modern services across the capital market. The Board of Directors and the Managing Director have announced passing a corresponding resolution.

Lars M?ller, CEO of SynBiotic SE, explains: "Canada is the flagship country when it comes to the cannabis industry. The sector there is particularly well developed, with a number of listed companies and billions in market capitalization. Above all, having our own Canadian listing makes it easier for us to gain access to specialized investors. In the Canadian capital market, we also ensure ourselves of a completely different degree of attention to and understanding of our issue - and can thus better exploit the opportunities to access capital."

All of this would be facilitated by the platform company being in the midst of its peer group on the new NEO Exchange. With the Canadian top dogs Tilray, Canopy Growth or the Cronos Group, a vastly improved comparability to that enjoyed in Europe would follow. M?ller continues: "Analysts, market observers and investors will look at us with different eyes - but so will the Canadian competition. Because at the latest, when they further expand into Europe, they will be on the lookout for cooperation partners. Therefore, our envisaged move to go public on the NEO Exchange is also a strategic step."

About SynBiotic SE SynBiotic SE is the first German listed cannabis company to pursue an EU-focused buy-and-build investment approach. The core business of the platform company is the research and development of new cannabinoid and terpene-based solutions to major social problems such as pain, sleep-disorders and anxiety. In addition, the platform deals with the production of various cannabinoids and develops and distributes pharmaceutical and dietary supplements as well as cosmetic products under its own brands.

End of Media Release Issuer: SynBiotic SE Key word(s): Finance

12.10.2021 Dissemination of a Press Release, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

Language: English Company: SynBiotic SE Barer Str. 7 80333 M?nchen

Germany E-mail: office@synbiotic.com Internet: https://www.synbiotic.com/ ISIN: DE000A3E5A59 WKN: A3E5A5 Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Tradegate Exchange EQS News ID: 1239995 ? End of News DGAP Media

1239995??12.10.2021?

@ dgap.de